| 182.09 0.15 (0.08%) | 11-28 13:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 216.27 | 1-year : | 252.61 |
| Resists | First : | 185.16 | Second : | 216.27 |
| Pivot price | 168.85  |
|||
| Supports | First : | 156.01 | Second : | 138 |
| MAs | MA(5) : | 179.62 |
MA(20) : | 164.9 |
| MA(100) : | 144.34 |
MA(250) : | 139.58 |
|
| MACD | MACD : | 8.1 |
Signal : | 6.4 |
| %K %D | K(14,3) : | 90.7 |
D(3) : | 88.5 |
| RSI | RSI(14): 79.9 |
|||
| 52-week | High : | 185.16 | Low : | 110.04 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BIIB ] has closed below upper band by 12.0%. Bollinger Bands are 105.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 183.97 - 184.9 | 184.9 - 185.49 |
| Low: | 178.52 - 179.77 | 179.77 - 180.56 |
| Close: | 180.16 - 182.03 | 182.03 - 183.23 |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Sat, 29 Nov 2025
A Look at Biogen's Valuation as It Expands Immunology Pipeline With Dayra Therapeutics Collaboration - simplywall.st
Fri, 28 Nov 2025
BIIB - Biogen Inc Stock Price and Quote - Finviz
Fri, 28 Nov 2025
Biogen shares could climb on Leqembi uptake – Jefferies - Proactive financial news
Tue, 25 Nov 2025
Why Biogen (BIIB) Is Up 7.4% After Announcing Dayra Immunology Collaboration and Pipeline Expansion - simplywall.st
Mon, 24 Nov 2025
How Do Investors Really Feel About Biogen Inc? - Benzinga
Mon, 24 Nov 2025
Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data? - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 147 (M) |
| Shares Float | 146 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 94.6 (%) |
| Shares Short | 5,640 (K) |
| Shares Short P.Month | 4,880 (K) |
| EPS | 10.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 124.11 |
| Profit Margin | 15.9 % |
| Operating Margin | 30.7 % |
| Return on Assets (ttm) | 5.7 % |
| Return on Equity (ttm) | 9.3 % |
| Qtrly Rev. Growth | 2.7 % |
| Gross Profit (p.s.) | 52.55 |
| Sales Per Share | 68.64 |
| EBITDA (p.s.) | 23.24 |
| Qtrly Earnings Growth | 19.2 % |
| Operating Cash Flow | 2,450 (M) |
| Levered Free Cash Flow | 2,140 (M) |
| PE Ratio | 16.59 |
| PEG Ratio | 0 |
| Price to Book value | 1.46 |
| Price to Sales | 2.65 |
| Price to Cash Flow | 10.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|